List of Excipients in Branded Drug BROMFENAC SODIUM

Generic Drugs Containing BROMFENAC SODIUM

Company	Ingredient	NDC	Excipient
Alembic Pharmaceuticals Limited	bromfenac sodium	46708-583	BENZALKONIUM CHLORIDE
Alembic Pharmaceuticals Limited	bromfenac sodium	46708-583	BORIC ACID
Alembic Pharmaceuticals Limited	bromfenac sodium	46708-583	EDETATE DISODIUM
Alembic Pharmaceuticals Limited	bromfenac sodium	46708-583	POVIDONE
Alembic Pharmaceuticals Limited	bromfenac sodium	46708-583	SODIUM BORATE
Alembic Pharmaceuticals Limited	bromfenac sodium	46708-583	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in BROMFENAC SODIUM?

# Of NDCs	Excipient
3	BENZALKONIUM CHLORIDE
3	BORIC ACID
3	EDETATE DISODIUM
3	POVIDONE
3	SODIUM BORATE
3	SODIUM HYDROXIDE

Bromfenac Sodium Excipient Strategy and Commercial Opportunities

Last updated: August 11, 2026

Bromfenac sodium is a mature ophthalmic NSAID with limited active-ingredient exclusivity but continuing commercial value in postoperative cataract care. The strongest opportunities are differentiated topical delivery systems: low-dose formulations, improved ocular residence time, preservative-free multidose packaging, reduced dosing frequency, and combination products. The primary commercial constraint is generic competition in bromfenac ophthalmic solution, particularly the 0.09% strength.

What is the commercial market for bromfenac sodium?

Bromfenac sodium is marketed primarily as an ophthalmic solution for the treatment of ocular inflammation and pain associated with cataract surgery. The principal branded products are:

Product	Strength	Manufacturer or sponsor	Primary positioning
Prolensa	0.07%	Bausch + Lomb	Once-daily postoperative ophthalmic NSAID
BromSite	0.075%	Sun Pharmaceutical Industries, through InSite Vision technology	Twice-daily postoperative ophthalmic NSAID using DuraSite technology
Xibrom	0.09%	ISTA Pharmaceuticals, later Bausch + Lomb	Earlier twice-daily bromfenac product; largely replaced by newer products
Generic bromfenac ophthalmic solution	Commonly 0.09%	Multiple ANDA holders	Lower-cost substitution

Bromfenac competes with ketorolac tromethamine, nepafenac, and diclofenac ophthalmic products. Its commercial differentiation is based on potency, dosing frequency, postoperative inflammation control, and delivery-system performance rather than on a new molecular entity strategy.

FDA-approved labeling identifies bromfenac ophthalmic products for postoperative inflammation and reduction of ocular pain in patients undergoing cataract surgery. Prolensa was approved in 2013, while BromSite was approved in 2016. The products are regulated as prescription ophthalmic solutions under new drug applications and abbreviated new drug applications. [1-3]

Which bromfenac sodium formulations are commercially relevant?

The main formulation platforms are conventional buffered aqueous solutions and viscosity-enhanced ocular delivery systems.

Conventional aqueous formulation

The conventional platform generally contains:

• Bromfenac sodium
• Boric acid
• Sodium borate
• Povidone
• Edetate disodium
• Sodium hydroxide for pH adjustment
• Purified water or water for injection
• Benzalkonium chloride in selected multidose products

Prolensa 0.07% uses a buffered aqueous formulation with povidone and edetate disodium. The formulation is designed to maintain bromfenac in solution, control pH, support ocular tolerability, and provide acceptable multidose stability. [1]

Viscosity-enhanced formulation

BromSite 0.075% uses the DuraSite ophthalmic delivery platform associated with InSite Vision. DuraSite is a polycarbophil-based mucoadhesive system intended to increase precorneal residence time and improve delivery to ocular tissues.

The strategic purpose of the platform is to offset bromfenac’s short ocular residence time after conventional instillation. A delivery system that prolongs contact can support reduced dosing frequency, improved adherence, and differentiation against generic bromfenac 0.09% solutions.

Generic 0.09% formulation

Generic products typically pursue therapeutic equivalence to the reference 0.09% ophthalmic solution. Their commercial strategy is usually based on:

• Lower manufacturing cost
• Standard aqueous processing
• Existing ophthalmic filling infrastructure
• Multisource pharmacy substitution
• Avoidance of protected formulation or delivery-system claims

Generic products generally have less freedom to introduce substantial excipient changes because formulation differences can affect bioequivalence, viscosity, preservative exposure, pH, osmolality, droplet size, and ocular tolerability.

What excipients are most important in bromfenac sodium ophthalmic products?

The excipient strategy must solve five formulation problems: aqueous solubility, chemical stability, ocular comfort, antimicrobial protection, and residence time.

Excipient class	Typical function	Strategic considerations
Boric acid and sodium borate	Buffering and tonicity control	Supports pH control and ocular tolerability
Sodium hydroxide	pH adjustment	Controls bromfenac ionization and stability
Povidone	Wetting, viscosity, and comfort	Can improve spreading and reduce precipitation risk
Edetate disodium	Chelation	Limits metal-catalyzed degradation and supports preservative performance
Benzalkonium chloride	Antimicrobial preservation	Effective in multidose products but creates chronic-exposure tolerability concerns
Polycarbophil or similar mucoadhesive polymer	Prolonged ocular residence	Supports reduced dosing frequency and formulation differentiation
Cyclodextrins	Solubilization	Potentially useful where precipitation or concentration limits arise
Nonionic surfactants	Wetting and dispersion	Can improve delivery but may increase irritation or regulatory complexity
Osmolality modifiers	Comfort and tonicity	Important for postoperative ocular tolerability
Antioxidants	Oxidative stability	Must be selected carefully because of ocular compatibility requirements

Buffer and pH design

Bromfenac sodium is a weakly acidic drug delivered in a buffered aqueous environment. pH affects ionization, solubility, hydrolysis, ocular comfort, and preservative activity. The commercial formulations use borate-based buffering, generally near physiologic ocular tolerability ranges.

A formulation should not maximize solubility at the expense of irritation. The preferred operating range is the narrow region that maintains a clear solution, minimizes precipitation during storage, and remains comfortable after instillation.

Povidone selection

Povidone is commercially attractive because it can improve wetting and provide modest viscosity without the complexity of a high-molecular-weight gel. Molecular-weight selection affects solution viscosity, drop formation, surface retention, and patient sensation.

A higher-viscosity povidone grade may improve retention but can create blurred vision, stringiness, or inconsistent dosing. A lower-viscosity grade provides less differentiation but is easier to process and fill.

Chelation with edetate disodium

Edetate disodium is useful in bromfenac formulations because trace metals can accelerate degradation and affect preservative performance. The excipient also supports product robustness during long-term storage in plastic ophthalmic containers.

The level must be optimized. Excessive chelator concentration can complicate compatibility studies and may affect container-closure performance or ocular tolerability.

Preservative strategy

Benzalkonium chloride remains commercially useful in multidose ophthalmic bottles because it provides established antimicrobial protection and manufacturing familiarity. Its limitation is ocular-surface toxicity, particularly with repeated administration or compromised ocular surfaces.

The most valuable preservative-related opportunities are:

1. Preservative-free unit-dose packaging.
2. Preservative-free multidose pump systems.
3. Reduced-benzalkonium formulations.
4. Alternative preservatives with lower ocular-surface burden.
5. Container systems that prevent microbial ingress without chemical preservatives.

A preservative-free product can command a premium if it demonstrates comparable stability, sterility assurance, usability, and postoperative tolerability.

What formulation patents protect bromfenac sodium products?

The active bromfenac molecule is mature, and basic compound protection is no longer the principal barrier to entry. Current value is concentrated in formulation, dosing, delivery-system, and method-of-use claims.

Relevant patent categories

Patent category	Potential commercial subject matter	Competitive value
Low-dose formulations	0.07% or 0.075% bromfenac solutions	Supports reduced active load and differentiated dosing
Viscosity-enhanced systems	Polycarbophil, carbomer, cellulose, or related polymers	Can support prolonged residence and dosing claims
Buffered solutions	Specific pH, buffer, chelator, and excipient ranges	Often difficult to design around if narrowly claimed
Postoperative methods	Once-daily or twice-daily use after cataract surgery	Can delay substitution where enforceable
Combination products	Bromfenac with antibiotics or other postoperative agents	Supports bundled surgical-care products
Container-closure systems	Preservative-free multidose delivery	Creates device and formulation barriers
Manufacturing methods	Sterile filtration, aseptic filling, particle control, and stability processes	May protect process know-how even where patent claims are narrow

The Prolensa and BromSite product strategies illustrate two different protection models. Prolensa emphasizes low concentration and once-daily administration. BromSite emphasizes a delivery platform intended to increase ocular residence time. Their commercial defensibility therefore rests on different claim clusters.

Patent expiration must be assessed at the patent-family level, not by the bromfenac sodium ingredient alone. FDA Orange Book listings, patent-term adjustments, pediatric extensions, terminal disclaimers, and litigation settlements can change the practical entry date. [4]

When does bromfenac sodium lose exclusivity?

Bromfenac sodium has already lost core active-ingredient exclusivity. The relevant commercial question is whether formulation or use patents delay generic substitution for a particular product.

Exclusivity element	Commercial status
New chemical entity exclusivity	Not available for current bromfenac products because bromfenac is an established active ingredient
Basic compound patent	Expired or commercially exhausted
Product-specific formulation protection	May remain relevant depending on the NDA and Orange Book listing
Method-of-use protection	May remain relevant for cataract-surgery indications or dosing regimens
Regulatory exclusivity	Product-specific and dependent on approval history
Generic substitution	Available where an ANDA has been approved and relevant barriers have expired or been resolved

The 0.09% bromfenac market is structurally exposed to generic competition. Lower-strength branded products and delivery-system products have greater protection potential, but their practical defense depends on the scope and remaining term of listed patents.

What is the Orange Book status of bromfenac sodium?

The FDA Orange Book identifies approved drug products, reference-listed drugs, therapeutic-equivalence evaluations, and patents submitted for certain approved products. Bromfenac ophthalmic products are prescription drug products regulated through NDAs, with generic versions approved through ANDAs where applicants demonstrate therapeutic equivalence to the relevant reference product. [4]

The Orange Book should be analyzed separately for:

• Prolensa NDA 021861
• BromSite NDA 207919
• Earlier bromfenac ophthalmic NDAs
• Approved ANDAs for bromfenac ophthalmic solution
• Listed formulation and method-of-use patents
• Patent-use codes and delisting activity

A patent listed against one bromfenac product does not automatically block an ANDA directed to another strength, formulation, or reference product.

Which companies are challenging bromfenac sodium products?

The competitive challenge is mainly multisource generic entry rather than biosimilar competition. Bromfenac is a small molecule, so the relevant pathway is an ANDA, not a biosimilar application.

Generic competition

Generic applicants can target conventional bromfenac ophthalmic solutions by relying on:

• Pharmaceutical equivalence
• Therapeutic equivalence
• Comparative analytical data
• In vitro performance testing
• Stability and sterility data
• Paragraph IV certification where applicable

The greatest generic vulnerability lies in conventional 0.09% solutions with standard buffers and preservatives. Products using proprietary mucoadhesive platforms, novel container systems, or distinctive low-dose regimens present higher formulation and patent-design risks.

Paragraph IV exposure

A Paragraph IV certification may allege that a listed patent is invalid, unenforceable, or not infringed. The filing can trigger patent litigation under the Hatch-Waxman Act and, in some circumstances, a 30-month stay of FDA approval. [5]

For bromfenac, the practical Paragraph IV risk depends on:

• Whether the ANDA targets the same reference product
• The number and scope of Orange Book-listed patents
• Whether the claims cover formulation, use, or delivery system
• The timing of patent expiry
• Whether a settlement includes a licensed or agreed launch date

Publicly reported litigation and settlement terms must be matched to the specific NDA, patent number, and ANDA. A generic approval alone does not establish freedom from all product or process claims.

What patent litigation affects bromfenac sodium?

Bromfenac litigation risk is concentrated around product-specific formulation and method-of-use patents rather than composition-of-matter claims.

Potential litigation issues include:

• Whether a low-dose solution falls within a claimed concentration range
• Whether a generic formulation infringes buffer or excipient limitations
• Whether a dosing regimen is protected as a method of use
• Whether a delivery system uses the same mucoadhesive polymer architecture
• Whether a generic label induces infringement of a protected postoperative indication
• Whether a patent claim is invalid for obviousness based on earlier ophthalmic NSAID formulations

Settlement agreements can produce an authorized-generic launch, delayed entry, or a license with restrictions on strength and dosage form. Commercial diligence should distinguish a final court judgment from an agreed dismissal or confidential settlement.

How strong is the bromfenac sodium patent estate?

The estate is moderate for differentiated products and weak for conventional solutions.

Asset type	Patent strength	Entry risk
Bromfenac active ingredient	Low	High generic exposure
Standard buffered 0.09% solution	Low to moderate	High
Low-dose 0.07% or 0.075% solution	Moderate	Medium
Mucoadhesive delivery platform	Moderate to strong if claims are narrow and validated	Medium
Preservative-free multidose system	Moderate	Medium
Combination product	Moderate to strong if clinical and formulation claims align	Medium
Manufacturing process	Moderate as trade secret; variable as patent	Medium
Postoperative dosing regimen	Variable	Depends on claim scope and label design

The strongest defensible position combines formulation claims with clinically meaningful differentiation. A patent that covers only routine buffer selection or conventional viscosity adjustment is more vulnerable to obviousness and design-around arguments than a patent tied to a demonstrated pharmacokinetic, dosing, or tolerability advantage.

What commercial opportunities exist for bromfenac sodium excipients?

Preservative-free postoperative product

A preservative-free bromfenac product could target cataract patients with ocular-surface disease, frequent postoperative dosing, or heightened sensitivity to benzalkonium chloride. The opportunity requires a reliable sterile container system and acceptable in-use stability.

Extended-residence formulation

A mucoadhesive or in situ gelling system could support once-daily dosing, reduced drainage, and improved adherence. The product must avoid excessive blur, stinging, and inconsistent drop delivery.

Bromfenac-antibiotic combination

A combination product could simplify postoperative regimens by combining an NSAID with an antibiotic. Commercial value would depend on compatibility, preservative strategy, stability, dosing alignment, and clinical evidence that the combination improves adherence without compromising either component.

Single-dose unit-dose packaging

Unit-dose packaging can remove preservative exposure and reduce contamination risk. The disadvantages are higher packaging costs, larger distribution volume, and more complex hospital or ambulatory-surgery workflows.

Advanced delivery systems

Potential platforms include:

• Nanoemulsions
• Lipid-based systems
• Cyclodextrin complexes
• Ocular inserts
• In situ gels
• Microparticles
• Low-volume high-concentration drops

The most commercially practical near-term technologies are likely preservative-free multidose pumps and modest-viscosity mucoadhesive solutions. More complex systems face greater regulatory and manufacturing burdens.

What manufacturing and IP barriers affect bromfenac sodium?

Manufacturing barriers are manageable for conventional products but increase materially with specialized delivery systems.

Key barriers include:

• Control of bromfenac concentration and uniformity
• Prevention of precipitation during storage
• Compatibility with low-density polyethylene or other ophthalmic containers
• Sterile filtration and aseptic filling
• Control of polymer hydration and viscosity
• Consistent drop size
• Microbial control during repeated use
• Extractables and leachables testing
• Container-closure integrity
• Photostability and oxidation control
• Reproducibility of mucoadhesive performance

The most valuable know-how may be process-based rather than patent-based. Polymer hydration sequence, mixing shear, filtration behavior, filling temperature, and container interaction can determine whether a formulation is commercially manufacturable.

How does bromfenac sodium compare with competing ophthalmic NSAIDs?

Drug	Common commercial strength	Dosing position	Differentiation
Bromfenac	0.07%, 0.075%, 0.09%	Once or twice daily depending on product	Potency and reduced dosing frequency
Nepafenac	0.1%, 0.3%	Three times daily or once daily depending on product	Prodrug conversion in ocular tissues
Ketorolac	0.4%, 0.5%	Often four times daily	Established generic, low cost
Diclofenac	0.1%	Multiple daily doses	Older, low-cost NSAID option

Bromfenac has a stronger premium-product position than generic ketorolac or diclofenac, but its price advantage is vulnerable when conventional bromfenac generics are available. Its commercial resilience depends on dosing convenience, delivery technology, and surgeon preference.

What generic launch scenarios exist for bromfenac sodium?

Scenario 1: Conventional 0.09% generic entry

This is the highest-probability entry scenario. The product competes primarily on price and pharmacy substitution. It places pressure on earlier 0.09% branded products and may expand use in price-sensitive settings.

Scenario 2: Limited substitution against low-dose products

A generic 0.09% product may not automatically substitute for a 0.07% or 0.075% product. The reference product, labeling, strength, formulation, and therapeutic-equivalence rating determine substitution potential.

Scenario 3: Delivery-system design-around

A generic applicant may avoid a mucoadhesive platform by using a conventional solution. This can permit market entry while leaving the delivery-system product commercially differentiated.

Scenario 4: Authorized generic or settlement launch

A branded company may use an authorized generic or license arrangement to control price erosion and manage Paragraph IV risk. Launch timing can depend on settlement terms rather than patent expiry alone.

Key Takeaways

• Bromfenac sodium is a mature small-molecule ophthalmic NSAID with no meaningful biosimilar opportunity.
• Conventional 0.09% bromfenac solutions have the highest generic-entry risk.
• Prolensa differentiates through low-dose, once-daily positioning.
• BromSite differentiates through a mucoadhesive DuraSite delivery platform.
• The most valuable excipient opportunities are preservative-free delivery, controlled viscosity, mucoadhesion, and container-based antimicrobial protection.
• Borate buffer, povidone, edetate disodium, pH control, and preservative selection are central to product performance.
• The strongest patent positions combine formulation, delivery-system, method-of-use, and clinically demonstrated dosing claims.
• Revenue exposure is concentrated in premium branded ophthalmic products because generic 0.09% entry can rapidly compress conventional-solution pricing.
• Manufacturing know-how involving polymer processing, sterile filling, container compatibility, and drop-size control can provide meaningful commercial protection.

FAQs

Can bromfenac sodium be formulated as a preservative-free ophthalmic product?

Yes. The most credible approaches are unit-dose containers and preservative-free multidose pumps. The product must demonstrate sterility throughout the labeled in-use period and maintain chemical and physical stability.

Which excipient is most important for extending bromfenac ocular residence time?

A mucoadhesive polymer, such as polycarbophil or a related polymer system, is generally more important than conventional povidone for materially increasing ocular residence time. Polymer concentration and rheology determine whether retention gains outweigh blur and discomfort.

Is bromfenac sodium suitable for a fixed-dose antibiotic combination?

Yes, but the combination requires compatibility, stability, preservative, dosing-frequency, and clinical-label analysis. The antibiotic must remain stable in the bromfenac formulation across the proposed shelf life.

What is the most defensible bromfenac product-development strategy?

A preservative-free, low-dose, extended-residence formulation with once-daily or reduced-frequency dosing offers the clearest differentiation from standard generic bromfenac solution.

Does a generic bromfenac 0.09% product automatically replace Prolensa or BromSite?

No. Automatic substitution depends on FDA therapeutic-equivalence ratings, the reference-listed drug, strength, dosage form, labeling, and pharmacy-substitution rules. A generic 0.09% product is not automatically therapeutically equivalent to a different-strength or delivery-system product.

References

1. Bausch + Lomb. (2023). Prolensa (bromfenac ophthalmic solution) 0.07% prescribing information. U.S. Food and Drug Administration.

2. Sun Pharmaceutical Industries, Inc. (2023). BromSite (bromfenac ophthalmic solution) 0.075% prescribing information. U.S. Food and Drug Administration.

3. U.S. Food and Drug Administration. (2016). BromSite approval letter and prescribing information. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov

5. U.S. Food and Drug Administration. (2024). Hatch-Waxman patent certification and Paragraph IV procedures. Center for Drug Evaluation and Research.